Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)

TerminatedOBSERVATIONAL
Enrollment

59

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 6, 2019

Study Completion Date

December 6, 2019

Conditions
X-Linked Adrenoleukodystrophy (X-ALD)Cerebral Adrenoleukodystrophy (CALD)Adrenoleukodystrophy (ALD)
Interventions
GENETIC

Allo-HSCT

Allogeneic Hematopoietic Stem Cell Transplantation

Trial Locations (13)

19104

The Children's Hospital of Philadelphia, Philadelphia

27705

Duke University Medical Center, Durham

55455

University of Minnesota, Minneapolis

90027

Children's Hospital Los Angeles, Los Angeles

94304

Stanford University, Palo Alto

02141

Boston Children's Hospital/Massachusetts General Hospital, Boston

Unknown

Hospital Austral, Buenos Aires

University Hospital Leipzig, Leipzig

Princess Maxima Center for Pediatric Oncology (PMC), Utrecht

Great Ormond Street Hospital, London

H3H 2R9

McGill University Health Centre, Montreal

00165

IRCCS Ospedale Pediatrico Bambine Gesú, Roma

M13 9WL

Central Manchester University Hospitals NHS Foundation Trust, Manchester

Sponsors
All Listed Sponsors
lead

Genetix Biotherapeutics Inc.

INDUSTRY

NCT02204904 - Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD) | Biotech Hunter | Biotech Hunter